Form 8-K Summary
Registrant: MedTech Acquisition Corporation (MTAC), which plans to rename itself TriSalus Life Sciences, Inc. upon closing of the proposed business combination.
Reporting date: May 13, 2023; filed May 15, 2023. The filing reports an amendment to the merger agreement with TriSalus Life Sciences, Inc.
Business Context and Transaction
MTAC, its wholly owned merger subsidiary, and TriSalus entered into a merger agreement on November 11, 2022, as subsequently amended. The transaction would result in TriSalus becoming a wholly owned subsidiary of MTAC, with TriSalus equity holders receiving MTAC common stock.
The May 13, 2023 amendment permits MTAC to seek stockholder approval to extend its business-combination deadline to no later than September 22, 2023. It also clarifies that greenshoe or other investor-held options will not count toward Available Closing Acquiror Cash and reduces the minimum Available Closing Acquiror Cash condition from $60 million to $35 million.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit or loss, cash flow, margin, debt, cash balance, or other operating financial metrics for MTAC or TriSalus.
The filing indicates that the transaction remains subject to minimum cash requirements, including the amended $35 million Available Closing Acquiror Cash threshold, potential stockholder redemptions, and the ability to obtain additional financing. The filing text does not provide a clear amount of available cash, anticipated financing, or projected post-closing liquidity.
Material Changes Versus Prior Disclosure
- The merger agreement was further amended on May 13, 2023.
- MTAC may seek an extension of its business-combination deadline through September 22, 2023.
- Investor-held options and greenshoe options are excluded from the calculation of Available Closing Acquiror Cash.
- The minimum Available Closing Acquiror Cash condition was reduced from $60 million to $35 million.
- The Form S-4 registration statement and related proxy statement/prospectus were not yet effective as of the filing.
Outlook, Risks, and Contingencies
Closing remains subject to stockholder approval, satisfaction or waiver of merger conditions, minimum cash requirements after redemptions, regulatory approvals, and other customary conditions. The transaction may be terminated or delayed, and MTAC may fail to obtain an extension before its business-combination deadline.
Additional risks identified include the ability to raise financing, maintain Nasdaq listing, achieve anticipated transaction benefits, and realize projected pro forma results. TriSalus-specific risks include reimbursement changes, clinical and regulatory setbacks for SD-101 and other product candidates, the ability to grow TriNav Infusion System sales, competition, market-size uncertainty, commercialization challenges, and the need to fund ongoing clinical development.
Management provides no operating or financial guidance in this filing. Forward-looking statements are subject to significant uncertainties, and the parties disclaim any obligation to update them.
Facts Investors Should Verify
- Whether MTAC stockholders approve the proposed business combination and any extension to September 22, 2023.
- Whether the $35 million minimum Available Closing Acquiror Cash condition is satisfied after redemptions and financing activities.
- The status and effectiveness of the Form S-4 registration statement and definitive proxy statement/prospectus.
- Actual cash, financing commitments, redemption levels, debt, and post-closing liquidity in subsequent filings.
- Regulatory, clinical, reimbursement, and commercialization developments affecting TriNav and SD-101.
- Whether the merger closes as contemplated and whether the combined company maintains its Nasdaq listing.